2016 NATIONAL OPAT CONFERENCE - BSAC · 2016 NATIONAL OPAT CONFERENCE ... F2-Paediatrics, ... Tip location, CLABSI, Midlines and Passports Andrew Jackson, IV Nurse Consultant,

DELEGATE BROCHURE

2016 NATIONALOPAT CONFERENCEICC BIRMINGHAM, 8TH-9TH DECEMBER 2016

#OPAT16

3CONTENTS

Welcome Letter

Floorplan

Information

Agenda - 8th November

Agenda - 9th November

Conference Speakers

Notes

Conference Sponsors

Poster Abstracts

4

5

6

7

9

14

40

43

51

CPD / CERTIFICATE OF PARTICIPATIONCertificates will be issued by e-mail within 5 working days of the Conference. The event has attracted 9 CPD points.

4 WELCOME LETTER

Welcome to the 2016 UK OPAT Initiative National Conference.

We are delighted to welcome you to this two day conference on Outpatient Parenteral Antimicrobial Therapy (OPAT).

The UK OPAT initiative is a multi-stakeholder project that supports, guides and encourages the establishment of standardised OPAT services throughout the UK wherever the clinical need may exist. This meeting is bringing together nearly 300 OPAT experts and we hope that you take the opportunity to share expertise, discuss success stories and learn about upcoming challenges in the OPAT setting.

We are delighted to welcome a broad mix of stakeholders from many centres across the UK who are looking to establish, strengthen or extend OPAT services. The conference has been organised with a number of key objectives in mind that include:

Defining new pathways for early discharge and admission avoidance for patients with infection

Commencing discussions around the establishment of a nursing network for OPAT

The value of OPAT in complex conditions

BSAC is very grateful to the range of companies present for their support of the conference which enables us to maintain registration fees at a minimum. We would encourage you, if you feel able, to please support our sponsors by visiting their stands during the networking breaks.

We very much hope that you enjoy the conference.

Professor Dilip Nathwani OBEPresident BSAC

5FLOORPLAN

SPONSORS

13PWA

Main Entra

nce

14 15

BSAC

1 2

4 3

5 6

78

9 10

1112

1 | Basilea2 | Fresenius Kabi & Calea3 | Lloyds Pharmacy Clinical Homecare6 | Astellas7 | MSD8 | MSD9 | CME Medical

10 | 3M & Vygon11 | Bard12 | Bard 13 | Cardiome14 | Baxter15 | PfizerPWA | Poster walk area

The portrait photographer is available in booth 5 and all registered attendees are entitled to a FREE headshot photograph.

6 INFORMATION

Conference admissionAdmission to conference is by delegate badge only. Please note that delegates are expected to wear name badges at all times.

Poster walks and free papersPosters will be presented in the Exhibition Hall (Hall 4) by those delegates who have successfully had their scientific abstracts accepted for inclusion at conference.

CateringRefreshments and lunches will be served in the main Exhibition Hall (Hall 4) during the designated break times.

CloakroomThe Cloakroom for all visitors is located on the ground floor of the ICC and there is a small charge.

Mobile phonesPlease ensure that all mobile phones are switched off or muted during scientific sessions.Where possible, please make and take your calls in common areas in the venue, away from conference rooms.

LiabilityNo responsibility whatsoever will be taken by the meeting, conference secretariat or the ICC for injury or damage to persons or property during the conference.

Event CoordinatorsPharmatologists Ltd, Ely, Cambs07763731054www.pharmatologists.co.uk | @pharmatologist

Function

Main Conference Session

Breakout session

Refreshments & Posters

Exhibition

Lunch

Cloakroom

Room

Hall 5

Hall 7

Hall 4

Hall 4

Hall 4

Ground Floor

7AGENDA - 8TH NOVEMBER 2016

0930 Welcome and Opening Remarks Dilip Nathwani, OBE, BSAC President

0940 How can OPAT help deliver the NHS Five Year Forward View? Philip Howard, Consultant Antimicrobial Pharmacist, Leeds Teaching Hospitals NHS Trust, Leeds

PLENARY SESSION: Clinical challenges in OPATChair, Dilip Nathwani, OBE, BSAC President

1010 Endocarditis Jonathan Sandoe, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds

1030 Spinal Infections Neil Ritchie, Clinical Lecturer in Infectious Diseases, Queen Elizabeth University Hospital, Glasgow

1050 Paediatrics - a special population? Sanjay Patel, Consultant Paediatrician, Southampton Children’s Hospital, Southampton

1115 REFRESHMENTS AND NETWORKING

PLENARY SESSION: Invited papersChair, Andrew Seaton, Consultant Physician, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde

1145 Clinical efficacy, cost-analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield OPAT service Chris Oyewole Durojaiye, Locum Consultant Physician, Royal Hallamshire Hospital, Sheffield

1200 A re- audit evaluating the management of OPAT bronchiectasis patients against current BTS guidelines Heather Boniface, F2-Paediatrics, Princess Royal Hospital, Telford

1215 Success of an outpatient parenteral antimicrobial therapy (OPAT) programme in a large UK paediatric hospital David Porter, Consultant in Paediatric Infectious Diseases, Alder Hey Hospital, Liverpool

1230 Self-administration of intravenous antibiotics for OPAT Emma Nickerson, Associate Specialist in Infectious Disease, Addenbrookes, Cambridge

8 AGENDA - 8TH NOVEMBER 2016

1245 LUNCH AND POSTER VIEWING

1400 PLENARY SESSION: Dalbavancin - The data, the patients and the practical considerations Sponsored by Cardiome

Chair: Dilip Nathwani, OBE, Dundee

WORKSHOPSWorkshop one: Treatment of skin and soft tissue infections in the ambulatory setting - the Nottingham experience LOCATION: HALL 5

Chair: Elizabeth Hart, Infectious Disease and Acute Medicine Physician, Nottingham Univerisity Hospitals Trust

1445 Learning outcome: Examining how to choose the right agent in the ambulatory care setting, including a review of licensed agents and drivers for prescribing - cost versus convenience versus stewardship versus stability Susan Snape, Consultant Microbiologist, Nottingham University Hospitals, Nottingham, Sarah Williams, Deputy Lead Specialist Nurse, Nottingham University Hospitals, Nottingham Tim Hills, OPAT Pharmacist, Nottingham University Hospitals, Nottingham Elizabeth Hart, Infectious Disease and Acute Medicine Physician, Nottingham University Hospitals, Nottingham

Workshop two: Community initiated OPAT services - Admission Avoidance LOCATION: HALL 7

Chair: Sharon Bamber, OPAT Service Lead, Wirral University Teaching Hospital NHS, Merseyside John Cunniffe, Consultant Microbiologist, Wirral University Teaching Hospital NHS, Merseyside

1445 Learning outcomes: Examining key factors in establishing admission avoidance services through safe, competency led services and appropriate patient selection Sharon Bamber, OPAT Service Lead, Wirral University Teaching Hospital NHS, Merseyside John Cunniffe, Consultant Microbiologist, Wirral University Teaching Hospital NHS, Merseyside

1545 REFRESHMENTS AND POSTER VIEWING


PARALLEL SESSIONSSESSION ONE: The challenges of IV and oral therapies in the OPAT setting LOCATION: HALL 5

Chair: Mark Gilchrist, Consultant Pharmacist in Infectious Diseases, Imperial College Healthcare NHS Trust, London

1615 IVOST: principles and practice in OPAT Andrew Seaton, Consultant Physician, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde

1635 Oral Versus Intra-venous Antibiotic Treatment for Bone and Joint Infections Matthew Scarborough, Infectious Diseases Consultant, Oxford University Hospitals NHS Trust, Oxford

1655 Resurgence of older oral therapies in OPAT Carolyn Hemsley, Consultant ID and Microbiology, Guys and St Thomas’s Hospital, London

1715 Panel discussion

SESSION TWO: Managing Vascular Access - facilitated by IVTEAM LOCATION: HALL 7

Chair: Andrew Jackson, IV Nurse Consultant, The Rotherham NHS Foundation Trust, Rotherham

1615 Introduction: Tip location, CLABSI, Midlines and Passports Andrew Jackson, IV Nurse Consultant, The Rotherham NHS Foundation Trust, Rotherham

1620 Infection Prevention and Vascular Access Martin Kiernan, Visiting Clinical Fellow, University of West London - GAMA Healthcare, London

1635 Vessel Health and Preservation Framework Tim Jackson, Consultant Anaesthetist & Intensivist at Calderdale & Huddersfield NHS Foundation Trust, Huddersfield

1655 ECG PICC Tip Location Gemma Oliver, Nurse Consultant Integrated IV Care at East Kent Hospitals University NHS Foundation Trust, Kent

1715 Panel Discussion

1730 WELCOME DRINKS AND NETWORKING


0730 Breakfast refreshments

PLENARY SESSION: Clinical lessons - invited papersChair: Mark Gilchrist, Consultant Pharmacist in Infectious Diseases, Imperial College Healthcare NHS Trust, London

0800 Clinical efficacy of daily parenteral infusions of meropenem and ampicillin in the OPAT setting James Pollard, Clinical Director, Hospital in the Home, Victoria, Australia

0815 Instructive Endocarditis Case Jonathan Sandoe, Associate Clinical Professor/Honorary Consultant Microbiologist, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds

0830 A Case of Unintended Consequences – lessons to be learned Beth White, Queen Elizabeth University Hospital, Glasgow

0845 Staphylococcus aureus Bacteraemia & optimal OPAT management - doing the right thing isn’t always easy! Eoghan de Barra, Consultant Infectious Diseases, Imperial College Healthcare Trust, London

PLENARY SESSION: Antimicrobial Stewardship and OPAT: Special populationsChair, Andrew Seaton, Consultant Physician, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde

0900 Treating MDR Negatives in OPAT Fiona Robb, Antimicrobial Pharmacist, NHS Greater Glasgow and Clyde, Glasgow

0925 Paediatric OPAT: an Australasian approach Penelope Bryant, Australasian Paediatric Antimicrobial Stewardship Group, Australia

0950 Q&A


PARALLEL SESSIONSSESSION ONE: Financial considerations in securing and extending OPAT services LOCATION: HALL 5

Chair: Sanjay Patel, Consultant Paediatrician, Southampton Children’s Hospital, Southampton

1000 Proving cost effectiveness in OPAT - what a commissioner needs to know Sue Snape, Consultant Microbiologist, Nottingham University Hospitals, Nottingham

1025 Funding pathways for OPAT Achyet Guleri, Clinical Microbiologist, Blackpool

1050 Q&A

SESSION TWO: Interactive Nursing Forum: Lessons from a regional service LOCATION: HALL 7

Chair: Carole Fry, Strategic Lead AMR Programme, Public Health England

1000 Community practice Kate Owen, District Nurse Community IV Team Leader, Dudley Group of Hospitals NHS Trust, West Midlands

1010 Acute practice Gemma Oliver, Nurse Consultant IV Care, East Kent Hospital University NHS Trust, Kent

1020 Establishing a regional the West Midland IV Forum Kate Owen, District Nurse Community IV Team Leader, Dudley Group of Hospitals NHS Trust, West Midlands

1030 Open floor discussion - should we establish a national forum?

1055 Next steps and close

1100 REFRESHMENTS AND POSTER VIEWING

1130 PLENARY SESSION: Driving efficiency in pathway design through patient self-administration Sponsored by Baxter Healthcare Ltd

Ann Cole, Baxter Healthcare Ltd


PLENARY SESSION: Research, policy and data - driving the clinical and nursing agendaCo-Chair, Andrew Seaton, Consultant Physician, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde

Co-Chair, Mark Gilchrist, Consultant Pharmacist in Infectious Diseases, Imperial College Healthcare NHS Trust, London

1215 NIHR Summary of OPAT work Jane Minton, Consultant in Infectious Diseases, Leeds Teaching Hospitals, Leeds

1235 Revised EPIC3 guidelines impact on OPAT Kate Owen, District Nurse Community IV Team Leader, The Dudley Group NHS Foundation Trust, Dudley

1255 Drug stability - why open access publication of stability data is essential Mark Santillo, Regional Quality Assurance Officer, Torbay & South Devon NHS Foundation Trust, Torquay

1315 Panel discussion

1335 CLOSING REMARKS - Where next for the OPAT in the UK? Mark Gilchrist, Consultant Pharmacist in Infectious Diseases, Imperial College Healthcare NHS Trust, London

13

www

www

www

‘The Role of Vaccines and Diagnostics in Reducing AMR’

14 SPEAKER BIOGRAPHY

Sharon has over 25 years’ experience working in the field of medical microbiology within the NHS, the majority of which has been spent working within clinical laboratories in the North West of England. Her current role utilises the clinical knowledge and managerial skills of a Clinical Scientist to enable the development of a new service incorporating best practice in infection control and antimicrobial stewardship.

Sharon BamberClinical Scientist (Microbiology & Infection Control) – OPAT Service Manager, Wirral University Teaching Hospital NHS Foundation Trust, Merseyside

8th December - 1445Chair: Session One - Financial considerations in securing and extending OPAT services

8th December - 1445Learning outcomes: Examining key factors in establishing admission avoidance services through safe, competency led services and appropriate patient selection

PRESENTATION DATE & TIME

15SPEAKER BIOGRAPHY

Eoghan de Barra received his medical degree in Dublin and proceeded to gain specialist training in Infectious Diseases and General Medicine in Ireland and South Africa. In 2011 he took a post as research fellow and lecturer in the department of Tropical Medicine and International Health at the Royal College of Surgeons in Ireland, Dublin and conducted malaria vaccine research work in Dublin and University of Oxford. In parallel, he worked as a consultant physician in the department of Infectious Diseases at Beaumont Hospital, Dublin, Ireland’s national neurosurgical centre. In 2014 he moved to London to work at Imperial College Healthcare NHS Trust as a Consultant in Infectious Diseases, where he is the clinical lead for the OPAT programme.

Eoghan de BarraConsultant in Infectious Diseases, Imperial College Healthcare NHS Trust, London

9th December - 0845Staphylococcus aureus Bacteraemia & optimal OPAT management - doing the right thing isn’t always easy!



A/Prof Penelope Bryant is an infectious diseases paediatrician and researcher who trained in Australia and the UK and who now works at the Royal Children’s Hospital in Melbourne. She is passionate about getting children home from hospital and leads the biggest paediatric acute home care service in Australasia. Her publications provide evidence for the use and misuse of IV antibiotics in hospital and at home and her research aims to discover how we can improve our provision of antibiotics for children.

Penelope BryantInfectious diseases Paediatrician, Royal Children’s Hospital, Melbourne, Australia

9th December - 0925Paediatric OPAT: an Australasian approach


17SPEAKER BIOGRAPHY

John Cunniffe has worked at Wirral University Teaching Hospital since 1999. During this period he has served as head of department and clinical lead for the joint laboratory project. He is currently Infection Control doctor for the organisation, and is actively engaged in antimicrobial stewardship and sepsis management initiatives. He has been involved in the Wirral OPAT project from the outset, sits on the steering group, and supports the weekly MDT review.

John CunniffeConsultant in Medical Microbiology,Wirral University Teaching Hospital NHS Foundation Trust, Merseyside


8th December - 1445Learning outcomes: Examining key factors in establishing admission avoidance services through safe, competency led services and appropriate patient selection



Dr. Chris Oyewole Durojaiye is a Consultant Physician in Infectious Diseases and Tropical Medicine at Royal Hallamshire Hospital, Sheffield, United Kingdom. He is also a Honorary Senior Clinical Lecturer at the University of Sheffield. Dr Durojaiye completed his specialty training in infectious diseases and medical microbiology in Cardiff. His special interests include outpatient parenteral antimicrobial therapy (OPAT), viral hepatitis and tropical infections.

Chris Oyewole DurojaiyeConsultant Physician in Infectious Diseases and Tropical Medicine,Department of Infection and Tropical Medicine, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

8th December - 1145Invited papersPaper: Clinical efficacy, cost-analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield OPAT service


19SPEAKER BIOGRAPHY

Mark Gilchrist is Consultant Pharmacist in Infectious Diseases at Imperial College Healthcare NHS Trust, and Honorary Senior Lecturer at Imperial College, London.

He is immediate past chair of the UK Clinical Pharmacy Association – Pharmacy Infection Network (UKCPA PIN), co-chair of the British Society for Antimicrobial Chemotherapy (BSAC) UK Outpatient Parenteral Antimicrobial Therapy (OPAT) Initiative and a spokesman for the Royal Pharmaceutical Society on antimicrobials.

Mark trained in Scotland before moving to London to concentrate on a career within infection. He has particular interests in antimicrobial stewardship strategies including OPAT, tuberculosis and critical care. Postgraduate education includes an MSc and non-medical independent prescribing status.

He has delivered many lectures and workshops on antimicrobial stewardship both at national and international level and has published around his areas of interest. He was awarded Faculty Fellow of the Royal Pharmaceutical Society in 2013, elected onto BSAC council in 2014 and was a member of the working group that reviewed and developed the 2015 Public Health England “Start Smart then focus” stewardship toolkit.

Mark GilchristConsultant Pharmacist in Infectious Diseases at Imperial College Healthcare NHS Trust, London

8th December - 1615Chair: Session one: The challenges of IV and oral therapies in the OPAT setting9th December - 0800Chair: PLENARY SESSION: Clinical lessons - Invited papers9th December - 1215Chair: PLENARY SESSION: Research, policy and data - driving the clinical and nursing agenda9th December - 1335CLOSING REMARKS - Where next for the OPAT in the UK?



Dr Achyut Guleri is a Consultant Clinical Microbiologist and Clinical Director of Laboratory Medicine at Blackpool Teaching Hospitals NHS Foundation Trust, and Honorary Senior Clinical Lecturer at the University of Central Lancashire.

He is also Lead Microbiologist for Lancashire Cardiac Centre, and strategic clinical lead for community/home IV therapy service (OPAT). His special interests include clinical mycology; patient safety; healthcare associated infections and antibiotic stewardship; quality, innovation, productivity and prevention (QIPP) and service development; transformational projects; and antibiotic resistance.

Dr Guleri studied at the Medical School, University of Rajasthan in India. He remained in the faculty of the Department of Medical Microbiology at SMS Medical School & Hospital, Jaipur, India for 9 years before accepting a position as Head of Clinical Mycology, Dammam Central Hospital for Eastern Province, Saudi Arabia. In 2006, Dr Guleri joined Blackpool Teaching Hospitals NHS Foundation Trust.

Achyut GuleriConsultant Clinical Microbiologist & Clinical Director, Pathology Services, Blackpool Teaching Hospitals NHS Foundation Trust, Hon. Senior Clinical Lecturer, University of Central Lancashire

9th December - 1025Funding pathways for OPAT


21SPEAKER BIOGRAPHY

Liz Hart is a Consultant in Acute medicine and Infectious Diseases at Nottingham University Hospitals NHS Trust. She has worked within the OPAT (Outpatient Parenteral Antibiotic Therapy) Department since its early days. She uses her wide ranging activities to increase awareness of the OPAT service. This includes increasing the numbers of acute medical patients that are eligible for OPAT with the aim of appropriately managing the patient with multiple co-morbidities safely in the outpatient setting.

Elizabeth HartConsultant in Infectious Diseases and Acute Medicine, Department of Infectious Diseases, Nottingham University Hospitals, Nottingham

8th December - 1445Chair: Workshop one - Treatment of skin and soft tissue infections in the ambulatory setting - the Nottingham experience

8th December - 1445Learning outcome: Examining how to choose the right agent in the ambulatory care setting, including a review of licensed agents and drivers for prescribing - cost versus convenience versus stewardship versus stability.



Carolyn Hemsley is Clinical Lead and Consultant in Infectious Diseases and Microbiology at Guy’s and St Thomas’ NHS Foundation Trust in London. She studied at Oxford University, completed her specialist training in Oxford and London and completed a PhD on Pneumococcal Virulence factors at Tufts University, Boston in collaboration with Imperial College, London. Appoint as a consultant at GSTT in 2007, she took over as Clinical Lead for Microbiology and Infectious Diseases in 2014. In her time as a consultant she has developed a bone infection service at GSTT and in 2009 set up an OPAT service which she continues to lead. Her clinical practice also involves management of infection in the non-HIV immunocompromised supporting Guy’ cancer centre. She has been involved with BSAC OPAT initiative since inception, PI for OVIVA at GSTT and is a member of UK Clinical Research Infection Group (UKCRIG).

Carolyn HemsleyMicrobiology and Infectious Disease Consultant, Department of Infection, Guy’s and St Thomas’ NHS Foundation Trust, London

8th December - 1655Resurgence of older oral therapies in OPAT


23SPEAKER BIOGRAPHY

Tim Hills is Lead Pharmacist, Antimicrobials and Infection Control at Nottingham University Hospitals NHS Trust (NUH).

He joined NUH in 1999 and has held a number of posts before becoming the antimicrobial pharmacist in 2003.

Tim is an active member of the UK Clinical Pharmacist’s Association Pharmacy Infection Network and was lead author of “The introduction and impact of an HTML based antibiotic guidelines website” the winning submission for the inaugural UKCPA Antimicrobial Management Award in 2006.

He chairs the East Midlands Antimicrobial Pharmacist’s Group.His interests include OPAT where he is part of the Nottingham OPAT team and BSAC OPAT Standards committee and the treatment and prevention of Clostridium difficile associated diarrhoea.

Tim HillsLead Pharmacist, Antimicrobials and Infection Control at Nottingham University Hospitals NHS Trust (NUH), Nottingham

8th December - 1445Learning outcome: Examining how to choose the right agent in the ambulatory care setting, including a review of licensed agents and drivers for prescribing - cost versus convenience versus stewardship versus stability



Philip Howard is a spokesman for the Royal Pharmaceutical Society on Antimicrobials, and for the charity Antibiotic-Action.

He was a member of the Dept of Health ARHAI Antimicrobial Stewardship Group that produced the original Start Smart then Focus Antimicrobial Stewardship Guidelines, and the HPA Primary Care Unit which helped produce the RCGP TARGET guidance on Antimicrobial Stewardship in Primary Care.

His research interests include Antimicrobial Stewardship, and led the first global hospital Antimicrobial Stewardship survey. He has been involved in AMS education and training across the world. In 2012, he won the GHP/GSK/UKCPA Clinical Leadership Award.

He is a committee / council member of:• RPS Expert Advisory Group on Antimicrobials• UKCPA Pharmacy Infection Group• Antibiotic Policies Group of European Society of Clinical Microbiology & Infectious Diseases

Philip HowardConsultant Pharmacist in Antimicrobials, Leeds Teaching Hospitals NHS Trust, AMR Project Lead at NHS-Improvement, Honorary Senior Lecturer at Leeds University, Leeds

8th December - 0940How can OPAT help deliver the NHS Five Year Forward View?


25SPEAKER BIOGRAPHY

Andrew has held a senior IV nurse role since 1995. Andrew splits his time between clinical, educational, research and leadership activities. However, the vast majority of his time is occupied with clinical work and leadership activities. In addition, Andrew is the creator and director of IVTEAM.com. Achievements include:• Introduction of a hospital-wide vascular access team.• Development of an integrated hospital and community IV service.• Development of a peripheral IV site monitoring tool ‘the VIP score’.• Development of peripheral IV bundle.• Development of PICC passport.• Qualified independent prescriber.• Organisational CLABSI rate of 0.3 per thousand catheter days.

Andrew JacksonIV Nurse Consultant and Director IVTEAM, The Rotherham NHS Foundation Trust

8th December - 1615Chair: Session Two - Managing Vascular Access - facilitated by IVTEAM

8th December - 1615Introduction: Tip location, CLABSI, Midlines and Passports



8th December - 0930Welcome and Opening Remarks

8th December - 1010Chair: PLENARY SESSION - Clinical challenges in OPAT8th December - 1400Chair: Dalbavancin - The data, the patients and the practical considerations


Professor Dilip Nathwani serves as National Specialty Adviser for Infectious Diseases to the Scottish Government Health Department, Recent Chair of the European Study Group on Antibiotic Policies and is President of the British Society for Antimicrobial Chemotherapy (BSAC). He also held the post of Director of Medical Education for NHS Tayside between 2006 and 2014.

Professor Nathwani chairs the Scottish Antimicrobial Prescribing Group - Government Funded National Stewardship Programme. He has authored more than 225 peer-reviewed publications and contributed extensively to national and international infection guidelines or policy statements. Professor Nathwani was awarded OBE for contribution to the treatment of infectious diseases in the Queen’s the New Year’s Honours List in 2015.

Professor Nathwani spearheaded the establishment of the UK OPAT Initiative in 2009 having a long standing interest in outpatient parentaral therapy.

Dilip Nathwani OBEPresident, BSAC Consultant Physician in Infectious Diseases and Honorary Professor of Infection at Ninewells Hospital & Medical School, Dundee

27SPEAKER BIOGRAPHY

Emma graduated from Cambridge University (UK) and Imperial College London and subsequently undertook a PhD at the Wellcome Unit in Thailand on “Defining the burden of morbidity and mortality due to invasive Staphylococcus aureus disease and the impact of drug resistance in Thailand”. She currently works at consultant level at Addenbrooke’s Hospital, Cambridge specialising in Bone and Joint Infection. In addition to working in Infectious Diseases, Emma forms part of the Bone Infection and OPAT teams as well as being a key member of the hospital’s project team tasked with setting up a regional Bone Infection Unit.

Emma NickersonAssociate Specialist in Infectious Diseases, Cambridge University Hospitals NHS Trust, Addenbrooke’s Hospital, Cambridge

8th December - 1230Self-administration of intravenous antibiotics for OPAT



Kate has over 21 years of registered nursing experience, 16 of which have been as a District Nurse in Dudley, West Midlands. Five years ago, Kate developed the Community Intravenous Team which encompasses the Oncology Outreach Service and the OPAT Service for Dudley Group NHS Foundation Trust.

In 2014, Kate was elected to the BSAC OPAT Standing Committee as a nurse representative and also gained the title of Queen’s Nurse for bringing care traditionally given in hospital out into the community.

Kate is passionate about providing safe and effective care in the community. She believes that it is essential to support patients and staff to achieve this aim.

Kate OwenDistrict Nurse community IV Team Leader, Dudley Group NHS Foundation Trust, West Midlands

9th December - 1000Interactive session to discuss practical nursing aspects to OPAT

9th December - 1225Revised EPIC3 guidelines impact on OPAT


29SPEAKER BIOGRAPHY

Dr Sanjay Patel is a paediatric infectious diseases and immunology consultant working at Southampton Children’s Hospital, England. He trained at Cambridge University medical school before completing his paediatric training in London followed by his higher specialist training in paediatric infectious diseases and immunology at St Mary’s Hospital London, Great Ormond Street Hospital London and Newcastle Children’s Hospital. He has also worked within the field of paediatric HIV and TB in Pietermaritzburg, South Africa.

His specific areas of interest are OPAT and antibiotic stewardship. In 2012, he introduced the first paediatric outpatient parenteral antibiotic therapy (p-OPAT) service in the UK. He led the BSAC p-OPAT workstream and chaired the joint BSAC / British Paediatric Allergy, Immunology and Infectious Diseases Group p-OPAT national working group tasked to develop good practice guidelines for the introduction and delivery of p-OPAT services in the UK, which were published in October 2014. He was a member of the NICE antibiotic stewardship guideline development group which published guidelines in 2015. He is on the BSAC OPAT standing committee and sits on BSAC council. He is co-lead for the module on antimicrobial stewardship for the ESPID on-line antibiotic management course and runs infectious diseases courses at Imperial College and in Iceland.

Sanjay PatelConsultant in Paediatric Infectious Diseases and Immunology, Southampton Children’s Hospital, Southampton

8th December - 1050Paediatrics- A Special Population?




James Pollard is Clinical Director of Hospital in the Home at Barwon Health in Geelong, Australia. James is an Infectious Diseases Physician who has an interest in patient-centred care and de-centralisation of healthcare.

James has been Clinical Director of HITH at Barwon Health since 2012, and also has appointments in antibiotic stewardship, HIV medicine, Hepatitis management, clinical infectious diseases and general medicine.

James PollardClinical Director, Hospital in the Home, Infectious Diseases PhysicianBarwon Health, University Hospital Geelong, Victoria, Australia

9th December - 0800Clinical lessons - free papers selected from abstractsPaper: Clinical efficacy of daily parenteral infusions of meropenem and ampicillin in the OPAT setting


31SPEAKER BIOGRAPHY

Fiona Robb is an Antimicrobial Pharmacist at the Queen Elizabeth University Hospital in NHS Greater Glasgow and Clyde. After graduating with a Masters in Pharmacy from Strathclyde University she continued her studies achieving an MSc in Clinical Pharmacy and Independent Prescriber qualification. OPAT is the highlight of her job because of the team approach drawing on each member’s expertise and knowledge to overcome the challenges of outpatient therapy and to ensure the best treatment outcomes for the patient.

Fiona RobbAntimicrobial PharmacistQueen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow

9th December - 0900Treating MDR Gram-Negative infections in OPAT



Neil is a Clinical Lecturer in Infectious Diseases at the University of Glasgow and a senior trainee in Infectious Diseases at the Queen Elizabeth University Hospital in Glasgow. He completed his PhD in pneumococcal immunobiology in 2015. His clinical interests include antimicrobial stewardship and management of complex post-surgical infection.

Neil RitchieClinical Lecturer in Infectious Diseases, Queen Elizabeth University Hospital, Glasgow

8th December - 1030Spinal Infections


33SPEAKER BIOGRAPHY

Jonathan Sandoe is Associate Clinical Professor of Medical Microbiology at the University of Leeds and Honorary Consultant Microbiologist at Leeds Teaching Hospitals NHS Trust. He was a founder member of the Leeds Endocarditis Service, a multidisciplinary team which has managed patients with infective endocarditis (IE) at LTHT since 2004. He has a longstanding interest in the management and prevention of IE.

Since 2002 he has been a member of the British Society for Antimicrobial Chemotherapy Endocarditis Working Party and in 2011 took over as chair. The Working Party has published guidelines concerning the management of IE as well as implantable cardiac electronic device infections. He was a member of the guideline development group for the National Institue for Health and Clinical Excellent (NICE) endocarditis prophylaxis guidelines and a British Heart Valve Society Working Party looking at models of service provision for patients with heart valve disease.

Jonathan SandoeAssociate Clinical Professor Medical Microbiology, Hon ConsultantUniversity of Leeds, Leeds Teaching Hospitals NHS Trust, Leeds

8th December - 1010Endocarditis

9th December - 0815Instructive Endocarditis Case



Mark Santillo has over 30 years’ experience in Pharmaceutical Quality Assurance and Quality control within the NHS, the past 9 years as Regional Quality Assurance Officer within South West England. Currently chair of the NHS Pharmaceutical Research and Development Group, Mark has been involved in the preparation of NHS standards for stability testing and assessment and also in the review of commercial stability studies including for biopharmaceuticals. Mark is an active member of the NHS Pharmaceutical Quality Assurance Committee (currently Vice-Chair) and the Pharmaceutical Aseptic Services Group and has produced guidance in a variety of areas relating to pharmaceutical QA for the NHS. He is also the module director for the Quality Control module of the PTQA course run by the University of Manchester, the NHS Representative on the Joint Pharmaceutical Analysis Group committee and a member of the BP Unlicensed Medicines Expert Advisory Group

Mark SantilloRegional Quality Assurance officer South West England, Torbay & South Devon NHS Foundation Trust, Devon

9th December - 1245Drug stability – why open access publication of stability date is essential


35SPEAKER BIOGRAPHY

Matt works in infectious diseases, general medicine and microbiology and is currently the lead physician for the OPAT service in Oxford. Much of his clinical time is spent on the bone infection unit, the main source of referrals to OPAT in Oxford. His research interests include Staph. aureus bacteraemia, orthopaedic infection and the prevention and control of health care associated infections.

Matthew ScarboroughConsultant in Clinical Infection, Oxford University Hospitals NHS Trust, Oxford

8th December - 1635Oral Versus Intra-venous Antibiotic Treatment for Bone and Joint Infections



Graduated Aberdeen University in 1989, and then completed specialist training in infectious diseases and general medicine in Dundee in 1999. Consultant Physician and Honorary Senior Lecturer in Infectious diseases and General Medicine in Glasgow since 2000. Established and lead the NHS Greater Glasgow and Clyde Health Board OPAT service, leads the Antimicrobial Management Team and is chair of the NHS GGC Antimicrobial Committee. Clinical lead on infection management within the Scottish Antimicrobial Prescribing Group. Council member of the British Society of Antimicrobial Chemotherapy and Co-Chair of the BSAC OPAT standing committee.

Andrew SeatonCo-Chair, Consultant Physician, Brownlee Centre, Gartnavel General Hospital, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde

8th December - 1615IVOST: principles and practice in OPAT9th December - 0900Chair: Antimicrobial stewardship and OPAT: Special populations

9th December - 1215Co-chair: Research, policy and data - driving the clinical and nursing agenda


37SPEAKER BIOGRAPHY

Sue Snape is the lead OPAT consultant at Nottingham University Hospitals NHS Trust. She established microbiology liaison with the trauma and orthopaedic teams, diabetic foot service and respiratory teams regarding the use of antimicrobials; and is education lead for Microbiology StRs in Nottingham.

She has developed the OPAT service from its inception in 2011 to the current time, now employing 25 staff members. In 2015/16 the service saw 620 patient episodes and saved 14998 bed days. One of the chief and ongoing challenges in establishing the service has been the securing of recurrent funding and negotiating service expansion with commissioners.

Sue SnapeConsultant in Infectious Diseases and Microbiology and lead OPAT consultant, Nottingham University Hospitals NHS Trust, Nottingham


9th December - 1000Proving cost effectiveness in OPAT - what a commissioner needs to know



Beth White initially studied and trained in Aberdeen and came to Glasgow for specialist training in Infectious Diseases in 2007. Throughout her final years in training, and since taking up her Consultant post in Glasgow she has been involved in the Glasgow OPAT service, including IT developments and improving front door OPAT use for SSTIs.

Beth WhiteConsultant in Infectious Diseases and Acute Medicine, Queen Elizabeth University Hospital, Glasgow

9th December - 0830Missed dx in OPAT with emphasis on lessons learned e.g. Missed diagnosis in OPAT


39SPEAKER BIOGRAPHY

Sarah Williams is the Deputy Lead Nurse within the OPAT Team at Nottingham University Hospitals. Alongside patient care, she has a keen interest in facilitating teaching sessions with hospital and community staff to ensure that care of IV lines is optimum. Since graduating from The University of Nottingham in October 2010, Sarah spent 18 months at as Staff Nurse on the Infectious Diseases Ward before joining the OPAT Team as a Specialist Nurse in June 2012.

Sarah WilliamsDeputy Lead OPAT Specialist Nurse Infectious Diseases Department, Nottingham University Hospitals, Nottingham



NOTES40

NOTES 41NOTES

NOTES42

43SPONSORS

STAND NO.

10

3MEvery intravenous (I.V.) site presents the potential for infection, dislodgement, skin damage, and other complications. These incidents can potentially cause patient discomfort and pain, extended hospital stays, additional therapy, and surgical intervention—even increased patient mortality.

3M science has delivered unique solutions that give you what you need to protect every I.V. catheter—from insertion to removal. Our broad portfolio of high-quality products makes it easy for you to choose and use the right solution: from barrier films to securement devices, antimicrobial dressings and disinfecting caps.

We can help you deliver compassionate care with evidence-based products to support patient and clinician safety, help prevent the risks of costly complications, and improve patient satisfaction.

STAND NO.

6

ASTELLASAstellas is a global pharmaceutical company dedicated to improving the health of people around the world. Committed to research in anti-infective care, Astellas is focusing on saving the lives of critically ill patients. Astellas key contacts:

Will Goulding – Anti Infectives, Brand Manager Email: [email protected] Ruth Rostron – Anti Infectives, Brand Manager Email: [email protected]

Astellas Pharma Ltd, 2000 Hillswood Drive, Chertsey, Surrey KT16 0RS

44 SPONSORS

STAND NO.

1

BASILEABasilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. It focuses on products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions.

STAND NO.

11/12

BARDBard Access Systems is an innovator and market leader in vascular access devices, creating products that have a positive impact on people’s lives. We develop, manufacture and distribute medical devices used by an array of practitioners in gaining access to the cardiovascular system for the purpose of delivering chemotherapy, blood products, antibiotics, drugs or nutrition.

Please visit our stand #11-12 to view the Site Rite 8 Ultrasound System with integrated Sherlock 3CG for vessel assessment, real time catheter visualization and ECG for tip confirmation. NICE recommends using Sherlock 3CG tip confirmation system from Bard to help with positioning PICCs.

45SPONSORS

STAND NO.

2

CALEACalea, part of Fresenius Kabi, is a specialised homecare company with over 25 years of experience in delivering high quality products and services across the UK. We work in partnership with healthcare professionals to provide care packages that meet local requirements and patient needs.

We provide a range of home therapy services in collaboration with clinical and commissioning teams to facilitate the patient’s journey from hospital to home.

STAND NO.

14

BAXTEROutpatient parenteral antimicrobial therapy (OPAT) offers several advantages to both patients and healthcare providers. It allows the patient to receive their treatment at home, and has been shown to deliver successful outcomes whilst reducing costs.

Baxter enables NHS Trusts to realise the benefits of OPAT in a number of ways. Baxter Infusor devices support moving suitable OPAT patients to a self-care model. Additionally we have a Hospital IV Therapy Specialist team that works with NHS nurses to train and support patients, ensuring they are comfortable with the transition from hospital to home and are ready to self-care.

With 30 years’ experience of providing high quality aseptic compounding supported by extensive stability data, we can help you release the burden on you aseptic unit by providing ready-to-use aseptically filled infusor pumps.

We can also offer you further support in the provision of OPAT through our homecare service, Baxter at Home.

www.baxter.com

46 SPONSORS

STAND NO.

13

CARDIOME

STAND NO.

9

CME MEDICALWe are CME MedicalWe believe in making clinical practice safer and more efficient. Our heritage is in developing specialist medical infusion devices and support that improve patient care in hospital, in the community and at home.

We consistently explore new ways to support healthcare professionals with our pioneering approach to developing medical technology products, services and training.

Kincraig Business Park, Kincraig Road, Blackpool, FY2 0PJT: 01253 206700 F: 01253 896648 [email protected] cmemedical.co.uk

47SPONSORS

STAND NO.

7/8

MSDToday’s MSD is a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, NJ, USA. Through our prescription medicines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships.

For more information, visit www.msd-uk.com

STAND NO.

2

FRESENIUS KABIFresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe. It is focused on the therapy and care of critically and chronically ill patients in both the hospital and home environment. The company develops, manufactures and markets products that offer efficient clinical outcomes combined with a commitment to quality and patient safety. With a corporate philosophy of “Caring for Life” the company’s goal is to improve the patient’s quality of life. This means that we continuously strive to develop our specialist skills in the fields of nutrition, infusion therapy, oncology and homecare. In doing so we provide innovative solutions to meet the highest standards of patient care

48 SPONSORS

STAND NO.

3

LLOYDS PHARMACY CLINICAL HOMECAREWe’re one of the most experienced providers of clinical homecare in the UK, and we’ve been supporting patients in this way since 1975. We provide care to more than 36,000 patients in their own home, ranging from straightforward delivery of medication to specialist nursing for complex conditions.

We used to be called Bupa Home Healthcare and in July 2016 we were acquired by the Celesio UK group of companies, a leading provider of healthcare services, including LloydsPharmacy. Being part of the Celesio UK group of companies means we are perfectly placed to address the evolving needs of healthcare in the UK.

We work in partnership with the NHS, pharmaceutical companies, and private medical insurers. Our range of treatments and conditions includes home parenteral nutrition, chemotherapy, IV antibiotics, enzyme replacement therapy, rheumatoid arthritis, multiple sclerosis and much more.

Because we manage the entire end-to-end homecare journey, using our own in-house staff and closely monitored processes, we are able to control and assure safety and quality at every stage – from prescription management through to medication delivery and nursing care in patients own homes.

We’re passionate about what we do and the difference we make to our patients’ lives. It’s this dedication that ensures we constantly deliver outstanding levels of care to our patients.

[email protected]

49SPONSORS

15STAND NO.

PFIZERToday, Pfizer offers patients access to a diverse portfolio of 14 anti-infective and anti-fungal medicines.

More than ever, the world needs new approaches to preventing and fighting infections.

Pfizer recently joined with over 100 industry partners to sign the Declaration on Combating Antimicrobial Resistance, announced in January at Davos, to call on governments to join industry in taking swift, coordinated action.

Pfizer sponsors the most comprehensive global antimicrobial resistance surveillance program in the industry. These programmes provide critical data regarding antibiotic resistance patterns that enable physicians and healthcare providers to make the most appropriate treatment choices for their patients. The goals of these programmes are to provide important information on resistance and to assess antibiotic stewardship.

Pfizer routinely sponsors and conducts medical education outreach to healthcare providers through a variety of channels, including medical symposia, to ensure appropriate utilisation of antibiotics and improve infection prevention and control.

Pfizer recently supported the British Society for Antimicrobial Chemotherapy and the University of Dundee to launch the Massive Open Online Course (MOOC) on antimicrobial stewardship.

Pfizer is proud to sponsor the OPAT Meeting and we look forward to sharing this meeting with you.

50 SPONSORS

10STAND NO.

VYGONWe are a leading supplier of medical and surgical devices with a reputation for delivering high quality products and excellence in customer service, helping healthcare professionals offer best practice solutions to patients.

Our ProductsOur product ranges extend across many therapeutic specialties, including vascular access, regional anaesthesia, IV management, neonatology and enteral feeding.

Our ServicesWe provide complementary training and technical support to customers to promote best practice in-line with current clinical guidelines.

T: 01793 748800 E: [email protected] W: www.vygon.co.uk

51POSTER ABSTRACTS

NO 1 | HEATHER BONIFACE, F2-PAEDIATRICS, PRINCESS ROYAL HOSPITAL, TELFORD A re- audit evaluating the management of OPAT bronchiectasis patients against current BTS guidelines

NO 2 | STEVE COLLINS, LEAD CLINICAL NURSE SPECIALIST IN OPAT, UNIVERSITY COLLEGE LONDON HOSPITALS Leaderflex IV catheters reduce length of inpatient stay and facilitate admission avoidance pathways for OPAT patients

NO 3 | CHRIS DUROJAIYE, LOCUM CONSULTANT PHYSICIAN, ROYAL HALLAMSHIRE HOSPITAL, SHEFFIELD Clinical efficacy, cost-analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield OPAT service

NO 4 | EMMA NICKERSON, ASSOCIATE SPECIALIST IN INFECTIOUS DISEASE, ADDENBROOKES, CAMBRIDGE Model plastic arm for teaching self-administration of antibiotics for OPAT

NO 5 | EMMA NICKERSON, ASSOCIATE SPECIALIST IN INFECTIOUS DISEASE, ADDENBROOKES, CAMBRIDGE Video demonstrations for supporting teaching of self-administration of intravenous antibiotics for OPAT

NO 6 | JAMES POLLARD, CLINICAL DIRECTOR, HOSPITAL IN THE HOME Clinical outcomes when treating Injecting Drug Users via OPAT

NO 7 | JAMES POLLARD, CLINICAL DIRECTOR, HOSPITAL IN THE HOME Clinical efficacy of daily parental infusions of meropenem and ampicillin in the OPAT Setting

NO 8 | DAVID PORTER, CONSULTANT IN PAEDIATRIC INFECTIOUS DISEASES, ALDER HEY HOSPITAL, LIVERPOOL Success of an outpatient parenteral antimicrobial therapy (OPAT) programme in a large UK paediatric hospital

NO 9 | TRANPIT SALUJA, CONSULTANT MICROBIOLOGIST, SANDWELL AND WEST BIRMINGHAM HOSPITAL NHS FT OPAT Service: Never event

NO 10 | TRANPIT SALUJA, CONSULTANT MICROBIOLOGIST, SANDWELL AND WEST BIRMINGHAM HOSPITAL NHS FT 24 hour infusion of piperacillin/ tazobactam delivered via an elastomeric device to bronchiectasis patients: SWBH experience

NO 11 | TRUPTI PATEL, CONSULTANT MICROBIOLOGIST, UNIVERSITY COLLEGE LONDON HOSPITALS Reduction of carbapenem use in OPAT – a realistic CQUIN target?

52 POSTER ABSTRACTS

NO 12 | JAMES ARTINGSTALL, MEDICAL STUDENT, UCL Risk factors for line complications in OPAT

NO 13 | A PATIENT CENTRED MIXED MODEL OPAT SERVICE IN A SMALL ACUTE GENERAL HOSPITAL IN EAST LONDON Jenniferth Aviles Moreta, OPAT and Vascular Acces CNS, Homerton Hospital

NO 14 | BRAMA HANUMUNTHADU, INFECTION SPR, ST.GEORGE’S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST, LONDON Antibiotic Toxicity and OPAT: Should relative risk of antibiotic toxicity change our prescribing behaviours?

NO 15 | RUTH CANTWELL, OPAT NURSE SPECIALIST, ALDERHEY Using an elastomeric pump to administer continuous infusions of antibiotics as part of an Outpatient Parenteral Antimicrobial Therapy (OPAT) programme

NO 16 | SARA HEDDERWICK, ID CONSULTANT, BELFAST HEALTH AND SOCIAL CARE TRUST Reduction of inappropriate use of OPAT with an assessment team as gatekeeper

NO 17 | CATHERINE HOPKINS, CLINICAL NURSE SPECIALIST, OUR LADY’S HOSPITAL FOR SICK CHILDREN A pilot National Paediatric OPAT programme

NO 18 | MAUREEN TWIDDY, SENIOR RESEARCH FELLOW, UNIVERSITY OF LEEDS Understanding patients’ experiences of Outpatient Parenteral Anti-microbial Therapy to inform service improvement: A qualitative study

NO 19 | MARY LOUISE DALY, OPAT NURSE, UNIVERSITY HOSPITAL BASEL Challenges of and first experience with setting up an OPAT service in a Swiss tertiary care hospital

NO 20 | TIM HILLS, NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST Is weekly therapeutic drug-level monitoring of Teicoplanin necessary in the OPAT setting?

NO 21 | WALTER ABELMAN, MEDICAL DIRECTOR, JDOC 365 OPAT Treatment in Private GP Clinic in North London

NO 22 | SALLY BOLSOVAR, OPAT CNS Introducing p-OPAT service to Sheffield Children’s Hospital

NO 23 | LAURA HARDING, OPAT RESEARCH AND TREATMENT ROOM NURSE, NOTTINGHAM UNIVERSITY HOSPITALS NUH TRUST Adverse drug reactions in patients receiving OPAT. How often does it occur and do we inform the GP?

NO 24 | LAURA HARDING, OPAT RESEARCH AND TREATMENT ROOM NURSE, NOTTINGHAM UNIVERSITY HOSPITALS NUH TRUST Reducing the use of heparin within the OPAT patient group.

53POSTER ABSTRACTS

NO 25 | LAURA HARDING, OPAT RESEARCH AND TREATMENT ROOM NURSE, NOTTINGHAM UNIVERSITY HOSPITALS NUH TRUST Tackling a concerning number of complications with midlines used within OPAT patients

NO 26 | TH NICOLAS WONG, SOECIALIST TRAINEE, ID AND MICROBIOLOGY, NUFFIELD ORTHOPEDIC CENTRE Economics of using Outpatient parenteral antimicrobial therapy (OPAT): A retrospective analysis of the Oxford University Hospitals NHS Trust OPAT service over an 18 month period

NO 27 | ANG LI, CORE MEDICAL TRAINEE, JOHN RADCLIFFE HOSPITAL Estimating demand for short term OPAT services in an acute general medicine unit.

NO 28 | MARY PEIRSE, SPR ID AND MICROBIOLOGY, ST.GEORGE’S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST, LONDON Stewardship Benefits of Infection Specialist-led OPAT Service

NO 29 | LIZ CRAIG, OPAT PHARMACIST, UNIVERSITY HOSPITALS SOUTH MANCHESTER An Audit to Assess the Cost Effectiveness of Continuous Antibiotic Infusions for Outpatients on Parenteral Antimicrobial Therapy (OPAT)

NO 30 | SILVANA CHRISTOU, CORE MEDICAL TRAINEE, CAMBRIDGE UNIVERSITY HOSPITAL Assessment of the effectiveness of PowerWand intravascular access in the Respiratory OPAT setting

NO 31 | SIMON WARREN, CONSULTANT, RNOH Experience of using the NORS registry

NO 32 | MELANIE STEPHENS, TRAINEE ADVANCED NURSE PRACTITIONER, SANDWELL AND WEST BIRMINGHAM HOSPITAL NHS FT The setting up of an Out-Patient Antibiotic Therapy (OPAT) clinic.

NO 33 | AUDREY ANGARA, OPAT SISTER, MILTON KEYNES UNIVERSITY HOSPITAL NHS FT OPAT Plus : Fast Track Access Making a Difference

NO 34 | PARSONS, TMF, GUYS AND ST THOMAS OPAT for aortic graft infection: 5 year experience from a large tertiary referral centre

NO 35 | RAJENI THANGARAJAH, HIGHLY SPECIALIST PHARMACIST, GUYS AND ST THOMAS OPAT in Flux – Assessment of Use in a Haemodialysis Population

NO 36 | TARIQ AZAMGARHI, SPECIALIST ANTIMICROBIAL PHARMACIST Clinical Outcomes in patients Treated with High Dose Daptomycin within The Royal National Orthopaedic Hospital OPAT Service

54 POSTER ABSTRACTS

NO 37 | CAROLINA CAPRARIO, ADDENBROOKES HOSPITAL Development of the RespOPAT (Respiratory outpatient parenteral antibiotic therapy service) through integration with existing services

NO 38 | JAMES HATCHER, CONSULTANT ID ANDMICROBIOLOGY, IMPERIAL COLLEGE HEALTHCARE NHS FT OMG from O&G: the challenges of managing tubo-ovarian abscesses with outpatient parenteral antibiotic therapy

NO 39 | CLAIRE VAN NISPEN TOT PANNERDEN, CONSULTANT - ID AND GENERAL MEDICINE, GUYS AND ST THOMAS OPAT in Haemodialysis - Review of Current Practice

NO 40 | JOANNE SHEMWELL, CLINICAL NURSE SPECIALIST, ROYAL WOLVERHAMPTON NHS FT Identifying the Challenges Associated with the Transition of OPAT Service Provision from Home to Clinic Based Delivery

NO 41 | KATY CRICK, CLINICAL NURSE SPECIALIST, RNOH Experience of Using the BSAC OPAT Patient Management System (PMS) to Support a Long Distance OPAT Service Model

NO 42 | KARA DOWLING, CLINICAL PHARMACY OPAT TECHNICIAN, RNOH Patient Satisfaction with a Long distance OPAT Model

NO 43 | S. ANPALAKHAN, ROYAL VICTORIA INFIRMARY Outpatient and Home Parental Antibiotic Therapy

NO 44 | FAYE CHAPPELL, PAEDIATRIC ID PHARMACIST, EVELINA LONDON CHILDREN’S HOSPITAL Ceftriaxone associated neutropenia – is it a cause for concern?

NO 45 | CHINTHIKA PIYASENA, EVELINA LONDON CHILDREN’S HOSPITAL & GUYS AND ST THOMAS Implementing a paediatric OPAT pathway for newborns with suspected early onset sepsis

NO 46 | ABI JENKINS, PHARMACIST, BSAC Antimicrobial Stability Data in Elastomeric Devices

Date of preparation: November 2016

British Society for Antimicrobial Chemotherapy53 Regent PlaceBirminghamB1 3NJ

www.e-opat.com

JOIN BSAC!ARE YOU A MEMBER OF BSAC?

Are you enjoying a wide-range of Membership benefits?

Would you like to be part of a progressive, ‘can-do’ Society that delivers high quality, low-cost education, often open access across the globe?

Did you know that the average saving on conference fees would have paid for your annual BSAC membership subscription fee with online access to JAC?

There are many reasons to join, and very few reasons not to!

PLEASE VISIT THE BSAC STAND AND JOIN TODAY. WE LOOK FORWARD TO WELCOMING YOU TO MEMBERSHIP!

Documents

2016 NATIONAL OPAT CONFERENCE - BSAC · 2016 NATIONAL OPAT CONFERENCE ... F2-Paediatrics, ... Tip location, CLABSI, Midlines and Passports Andrew Jackson, IV Nurse Consultant,